OTCMKTS:BPMUF Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis $77.40 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsShort Interest About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Basilea Pharmaceutica alerts:Sign Up Key Stats Today's Range$77.40▼$77.4050-Day Range$60.28▼$77.4052-Week Range$59.29▼$77.40VolumeN/AAverage VolumeN/AMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Basilea Pharmaceutica Ltd. is a Swiss biopharmaceutical company focused on developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology applications. The company was established in 2000 as a spin-off from Roche and is headquartered in Basel, Switzerland. Basilea’s commercial portfolio includes Cresemba (isavuconazole), an antifungal used to treat invasive aspergillosis and invasive mucormycosis, and Zevtera (ceftobiprole), a cephalosporin antibiotic used for certain serious bacterial infections. The company also maintains a development pipeline targeting drug-resistant pathogens and other areas of high unmet medical need. Basilea supplies its products in multiple international markets through a combination of direct commercial operations and partnerships. Its medicines are marketed across Europe and in other regions, including the United States, depending on the product and applicable regulatory approvals. The company is listed on the SIX Swiss Exchange and its shares also trade in the United States over the counter.AI Generated. May Contain Errors. Read More Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMUF Stock News HeadlinesBasilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactamMay 28, 2026 | globenewswire.comBasilea shareholders approve all proposals of the board of directors at the 2026 annual general meetingApril 15, 2026 | globenewswire.comElon’s AI Phone is comingRumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.September 26 at 1:00 AM | Stansberry Research (Ad)Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420April 9, 2026 | globenewswire.comBasilea announces start of first‑in‑human study of novel antibiotic BAL2420March 23, 2026 | globenewswire.comBasilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactamFebruary 25, 2026 | globenewswire.comBasilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call TranscriptFebruary 17, 2026 | seekingalpha.comBasilea Pharmaceutica AG GAAP EPS of CHF 3.14, revenue of CHF 232.4MFebruary 17, 2026 | seekingalpha.comSee More Headlines BPMUF Stock Analysis - Frequently Asked Questions How have BPMUF shares performed this year? Basilea Pharmaceutica's stock was trading at $63.25 on January 1st, 2026. Since then, BPMUF shares have increased by 22.4% and is now trading at $77.40. Does Basilea Pharmaceutica have any subsidiaries? The following companies are subsidiaries of Basilea Pharmaceutica: Conec UK Limited. How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:BPMUF CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees189Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.59 Current Ratio5.11 Quick Ratio4.68 Sales & Book Value Annual Sales$280.43 million Price / Sales3.63 Cash Flow$3.85 per share Price / Cash Flow20.11 Book Value$11.73 per share Price / Book6.60Miscellaneous Outstanding Shares13,170,000Free FloatN/AMarket Cap$1.02 billion OptionableNot Optionable Beta0.22 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:BPMUF) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredThe No. 1 move you need to make before Musk’s “Starphone” goes mainstreamTech forecaster Josh Baylin, who briefed Congress on the iPhone years before its release, says Elon Musk is bu...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Basilea Pharmaceutica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPMUF Stock Alerts